This Year Marks the 30th Anniversary of Actim® PROM
The approaching end of the year offers a wonderful opportunity to reflect on a major milestone we have been celebrating this year: the 30th anniversary of Actim® PROM.
Since its launch in 1995, the rapid test Actim® PROM has been trusted by healthcare professionals in obstetrics worldwide for its reliable detection of premature rupture of fetal membranes (PROM)—a condition that can pose serious risks for both the pregnant person and baby if not identified quickly and accurately.
With the support of our global network of passionate distributors, Actim® PROM has contributed to the care pathways of 12 million babies around the globe. This milestone reflects not only the reach of our technology but also the dedication of our distributors who help bring it to healthcare systems worldwide.
“At Actim, we are committed to advancing maternal care through scientific excellence and solutions that make a difference. The long-standing success of Actim® PROM highlights the vital role that rapid and accurate diagnostic tools play in supporting clinical decision-making and improving outcomes for babies and their families.”, says Siv Schalin, Managing Director at Actim.
The technology behind Actim® PROM remains at the heart of its reliability. Based on IGFBP-1— a highly specific biomarker for PROM—the test gives clinicians confidence in its diagnostic precision. “The antibody used in Actim® PROM is so specific that common contaminants such as vaginal blood, semen, urine, vaginal medications, bathing products or infectious agents do not affect the test result, making it a reliable tool for clinical decision-making”, explains Paula Luokola, Head of R&D at Actim.
Today, Actim PROM continues to be manufactured in Finland, reflecting our long-standing tradition of Nordic scientific excellence and commitment to quality. We are honored to continue the work that began 30 years ago, advocating for the health and well-being of babies and their families around the world.
As we celebrate this anniversary, we are also looking ahead. Our ongoing research and development efforts continue to shape the future of maternal diagnostics, with the goal of improving maternal health outcomes worldwide.
We look forward to many more years of innovation, collaboration, and positive global impact.
